GBIO News and Press, Generation Bio Co. From 03/31/23

2023-03-31 13:02:23 ET Summary Last week, Generation Bio announced a strategic collaboration with Moderna worth $5m upfront plus a $40m equity investment. Generation has been working on Lipid Nanoparticle Delivery Technology for gene therapies. The company has made little prog...

2023-03-23 10:53:32 ET Investing in penny stocks can be a lucrative but also volatile endeavor. For those unfamiliar, “ penny stocks ” are typically defined as stocks under $5. They may seem like a risky investment, but cheap stocks can also offer significant upside potent...

2023-03-23 10:06:23 ET Gainers: ZyVersa Therapeutics ( ZVSA ) +33% . Aziyo Biologics ( AZYO ) +29% . Generation Bio ( GBIO ) +20% . HTG Molecular Diagnostics ( HTGM ) +16% . scPharmaceuticals ( SCPH ) +15% . Losers:...

Collaboration will extend the applications of each company’s platform through discovery and development of novel lipid nanoparticles using Generation Bio’s proprietary stealth cell-targeted lipid nanoparticle (ctLNP) delivery system Moderna has acquired an option to license ...

CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company will participate in the Novel LNPs Targeting Diverse Tissues panel at ...

CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in t...

Generation Bio press release ( NASDAQ: GBIO ): Q4 GAAP EPS of -$0.55 beats by $0.02 . Cash, cash equivalents and marketable securities were $279.1 million as of December 31, 2022. The company continues to believe that its cash position will fund its operating pl...

— Company expects to announce data for Factor VIII expression in non-human primates in 2023 — Strong cash balance of $279.1M provides expected runway into 2025 CAMBRIDGE, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co . (Nasdaq: GBIO), a biotechnology...

CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company will present at the 41 st Annual J.P. Morgan Healthcare Conference...

Generation Bio press release ( NASDAQ: GBIO ): Q3 GAAP EPS of -$0.53 beats by $0.14 . Cash, cash equivalents and marketable securities were $301.2 million as of September 30, 2022, compared with $375.1 million in cash and cash equivalents as of December ...